Becton, Dickinson and Co. reported $5.3B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Abbott USD 13.01B 423M Sep/2026
Agilent USD 1.88B 43M Jun/2026
Align Technology USD 1.02B 40M Sep/2026
AngioDynamics USD 79.43M 3.72M Sep/2025
Baxter International USD 2.98B 20M Sep/2026
Becton, Dickinson and Co. USD 5.3B 300M Sep/2026
Bio-Rad Laboratories USD 656.4M 5.4M Sep/2026
Boston Scientific USD 5.14B 300M Sep/2026
Cooper Companies USD 1.07B 15.3M Jun/2026
Danaher USD 6.55B 254M Sep/2026
Dentsply International USD 836M 62M Sep/2026
Dexcom USD 1.34B 30M Sep/2026
Edwards Lifesciences USD 1.72B 20M Sep/2026
Globus Medical USD 763.72M 25.89M Sep/2026
Insulet USD 842M 40.3M Sep/2026
Integra LifeSciences USD 411.18M 7.62M Sep/2026
Intuitive Surgical USD 3.05B 158.7M Sep/2026
J&J USD 25.4B 89M Sep/2026
Medtronic USD 9.8B 0 Jun/2026
Solventum Corp USD 1.95B 250M Sep/2026
Stryker USD 6.5B 100M Sep/2026
Tandem Diabetes Care USD 283.69M 29.09M Sep/2026
Teleflex USD 567.8M 2.5M Sep/2026
Terumo JPY 312.69B 881M Sep/2026
Thermo Fisher Scientific USD 12.14B 147M Sep/2026
Zimmer Biomet Holdings USD 2.06B 120M Sep/2026